{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:39:26Z","timestamp":1790368766253,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.esmoop.2022.100497","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:09:25Z","timestamp":1653509365000},"page":"100497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"S.","family":"Michaleas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moreno Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mueller-Berghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Sarac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"van der Elst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"M\u00fcller-Egert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Enzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pignatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2022.100497_bib1","first-page":"31","article-title":"Breast cancer statistics, 2015: convergence of incidence rates between black and white women","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100497_bib2","doi-asserted-by":"crossref","first-page":"djv048","DOI":"10.1093\/jnci\/djv048","article-title":"Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state","volume":"107","author":"Kohler","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"35","key":"10.1016\/j.esmoop.2022.100497_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004614","article-title":"Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database","volume":"95","author":"Plasilova","year":"2016","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100497_bib4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100497_bib5","first-page":"1071","article-title":"The epidemiology of triple-negative breast cancer, including race","volume":"20","author":"Trivers","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100497_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.hoc.2013.05.003","article-title":"The management of early-stage and metastatic triple-negative breast cancer: a review","volume":"27","author":"Anders","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100497_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","article-title":"Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design","volume":"9","author":"Kassam","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100497_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100497_bib9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10549-012-2008-6","article-title":"Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial","volume":"133","author":"Brufsky","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100497_bib10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","volume":"30","author":"Park","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100497_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10549-010-0736-z","article-title":"Adjuvant therapy of triple negative breast cancer","volume":"120","author":"Perez","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2022.100497_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.critrevonc.2016.01.021","article-title":"Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer","volume":"100","author":"Twelves","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2022.100497_bib13","first-page":"25","article-title":"A\u00a0review of systemic treatment in metastatic triple-negative breast cancer","volume":"10","author":"Zeichner","year":"2016","journal-title":"Breast Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100497_bib14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int J Oncol"},{"issue":"suppl 23","key":"10.1016\/j.esmoop.2022.100497_bib15","first-page":"5857s","article-title":"In\u00a0vitro and in\u00a0vivo reactivity of an internalizing antibody, RS7, with human breast cancer","volume":"55","author":"Shih","year":"1995","journal-title":"Cancer Res"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2022.100497_bib16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/1097-0142(19940201)73:3+<816::AID-CNCR2820731311>3.0.CO;2-T","article-title":"Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts","volume":"73","author":"Stein","year":"1994","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100497_bib17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1158\/1535-7163.MCT-12-1170","article-title":"Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers","volume":"12","author":"Govindan","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"10.1016\/j.esmoop.2022.100497_bib18","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.esmoop.2022.100497_bib19","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","article-title":"Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate (sacituzumab govitecan)","volume":"21","author":"Sharkey","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100497_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.18632\/oncotarget.27342","article-title":"Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas","volume":"11","author":"Lopez","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2022.100497_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer","volume":"10","author":"Perrone","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100497_bib22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41598-020-58009-3","article-title":"Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan","volume":"10","author":"Zeybek","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100497_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100497_bib24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics","volume":"57","author":"de Man","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"30","key":"10.1016\/j.esmoop.2022.100497_bib25","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.2217\/fon-2021-0868","article-title":"A\u00a0plain language summary of the ASCENT study: sacituzumab govitecan for metastatic triple-negative breast cancer","volume":"17","author":"Bardia","year":"2021","journal-title":"Future Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2022.100497_bib26","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2022.100497_bib27","doi-asserted-by":"crossref","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.esmoop.2022.100497_bib29","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100497_bib30","first-page":"759","article-title":"Trop2 is a potential biomarker for the promotion of EMT in human breast cancer","volume":"40","author":"Zhao","year":"2018","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100497_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yexmp.2012.08.004","article-title":"Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer","volume":"94","author":"Lin","year":"2013","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100497_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1399-0004.2009.01202.x","article-title":"Comprehensive mutational analysis of BRCA1\/BRCA2 for Korean breast cancer patients: evidence of a founder mutation","volume":"76","author":"Seong","year":"2009","journal-title":"Clin Genet"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100497_bib33","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1634\/theoncologist.2016-0067","article-title":"Biology and management of patients with triple-negative breast cancer","volume":"21","author":"Sharma","year":"2016","journal-title":"Oncologist"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292200117X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292200117X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:14Z","timestamp":1761856154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292200117X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S205970292200117X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100497","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100497"}}